Septerna, Inc. (NASDAQ:SEPN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $43.1429.

SEPN has been the subject of several analyst reports. Truist Financial upped their price target on shares of Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. JPMorgan Chase & Co. upped their price target on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th.

Insider Transactions at Septerna

In other news, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at approximately $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 78,453 shares of company stock valued at $2,192,969. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Septerna

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its stake in Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after buying an additional 1,260,409 shares in the last quarter. Vanguard Group Inc. raised its stake in Septerna by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after buying an additional 104,394 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in Septerna by 8.1% in the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after buying an additional 100,000 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after purchasing an additional 329,264 shares in the last quarter. Finally, First Light Asset Management LLC bought a new position in shares of Septerna during the fourth quarter valued at approximately $17,308,000.

Septerna Stock Down 3.4%

NASDAQ SEPN opened at $24.97 on Friday. The company has a 50-day simple moving average of $26.16 and a two-hundred day simple moving average of $25.26. Septerna has a 12-month low of $6.09 and a 12-month high of $32.63. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -22.50 and a beta of 3.50.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. Equities analysts expect that Septerna will post -1.57 earnings per share for the current fiscal year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.